Iterum Therapeutics plc (NASDAQ:ITRM) Sees Large Growth in Short Interest

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 2,530,000 shares, a growth of 1,082.8% from the October 15th total of 213,900 shares. Based on an average daily trading volume, of 2,330,000 shares, the short-interest ratio is presently 1.1 days. Approximately 11.5% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Iterum Therapeutics in a research note on Tuesday, September 10th.

Iterum Therapeutics Stock Down 9.8 %

Shares of NASDAQ:ITRM traded down $0.14 during trading on Thursday, reaching $1.29. The stock had a trading volume of 845,463 shares, compared to its average volume of 955,001. The stock has a market cap of $29.30 million, a P/E ratio of -0.72 and a beta of 2.25. The business has a fifty day moving average price of $1.15 and a 200-day moving average price of $1.24. Iterum Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $2.50.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.22. As a group, equities analysts forecast that Iterum Therapeutics will post -1.19 EPS for the current year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.